Alzheimer's disease: Clinical implications of the apolipoprotein E genotype

Neurology

Volumn 48, Issue 5 SUPPL. 6, 1997, Pages

  Farlow, Martin R ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN E; NEUROPROTECTIVE AGENT; SELEGILINE; TACRINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; GENDER; GENETIC RISK; GENOTYPE; HUMAN; ONSET AGE; PHARMACOGENETICS; PRIORITY JOURNAL;

EID: 0030970412     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.48.5_suppl_6.30s     Document Type: Article

References (46)

1. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late-onset families. Science 1993;261:921-923.
2. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele ∈4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-1472.
3. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342:697-699.
4. Tsai M-S, Tangalos EG, Petersen RC, et al. Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet 1994;54: 643-649.
5. Lucotte G, Turpin J-C, Landais P. Apolipoprotein E-∈4 allele doses in late-onset Alzheimer's disease. Ann Neurol 1994;36: 681-682.
6. Mayeux R, Stern Y, Ottman R, et al. The apolipoprotein ∈4 allele in patients with Alzheimer's disease. Ann Neurol 1993; 34:752-754.
7. Liddell M, Williams J, Bayer A, Kaiser F, Owen M. Confirmation of association between the ∈4 allele of apolipoprotein E and Alzheimer's disease. J Med Genet 1994;31:197-200.
8. Brousseau T, Legrain S, Berr C, Gourlet V, Vidai O, Amouyel P. Confirmation of the ∈4 allele of the apolipoprotein E gene as a risk factor for late-onset Alzheimer's disease. Neurology 1994;44:342-344.
9. Jarvik GP, Larson EB, Goddard K, Kukull WA, Schellenberg GD, Wijsman EM. Influence of apolipoprotein E genotype on the transmission of Alzheimer's disease in a community-based sample. Am J Hum Genet 1996;58:191-200.
10. Hendrie HC, Hall KS, Hui S, et al. Apolipoprotein E genotypes and Alzheimer's disease in a community study of elderly African Americans. Ann Neurol 1995;37:118-120.
11. Nalbantoglu J, Gilfix BM, Bertrand P, et al. Predictive value of apolipoprotein E genotyping in Alzheimer's disease: results of an autopsy series and an analysis of several combined studies. Ann Neurol 1994;36:889-895.
12. Peacock ML, Fink JK. ApoE ∈4 allelic association with Alzheimer's disease: independent confirmation using denaturing gradient gel electrophoresis. Neurology 1994;44:339-341.
13. Hendrie HC, Osuntokun BO, Hall KS, et al. Prevalence of Alzheimer's disease and dementia in two communities: Nigerian Africans and African Americans. Am J Psychiatry 1995; 152:1485-1492.
14. Lehtimaki T, Moilanen T, Nikkari T, et al. Regional differences in apolipoprotein E polymorphism in Finland. Ann Med 1991;23:61-66.
15. Sobel E, Louhija J, Sulkava R, et al. Lack of association of apolipoprotein E allele ∈4 with late-onset Alzheimer's disease among Finnish centenarians. Neurology 1995;45:903-907.
16. Rebeck GW, Perls TT, West HL, Sodhi P, Lipsitz LA, Hyman BT. Reduced apolipoprotein ∈4 allele frequency in the oldest old Alzheimer's patients and cognitively normal individuals. Neurology 1994;44:1513-1516.
17. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late-onset Alzheimer disease. Nature Genet 1994;7:180-184.
18. Talbot C, Lendon C, Craddock N, Shears S, Morris JC, Goate A. Protection against Alzheimer's disease with apoE ∈2 [letter]. Lancet 1994;343:1432-1433.
19. Benjamin R, Leake A, McArthur FK, et al. Protective effect of apoE ∈2 in Alzheimer's disease [letter]. Lancet 1994;344:473.
20. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 1995;273:1274-1278.
21. Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of ApoE genotyping the prediction of outcome in patients with memory impairment. Neurology 1996; 46:149-154.
22. Frisoni GB, Govoni S, Geroldi C. Gene dose of the ∈4 allele of apolipoprotein E and disease progression in sporadic lateonset Alzheimer's disease. Ann Neurol 1995;37:596-604.
23. Kurz A, Egensperger R, Haupt M, et al. Apolipoprotein E ∈4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology 1996;47:440-443.
24. Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 1996;47: 444-448.
25. Payami H, Montee KR, Kaye JA, et al. Alzheimer's disease, apolipoprotein E4, and gender. JAMA 1994;271:1316-1317.
26. Corder EH, Saunders AM, Strittmatter WJ, et al. The apolipoprotein E E4 allele and sex-specific risk of Alzheimer's disease. JAMA 1995;273:373-374.
27. Farrer LA, Cupples LA, van Duijn CM, et al. Apolipoprotein E genotype in patients with Alzheimer's disease: implications for the risk of dementia among relatives. Ann Neurol 1995;38: 797-808.
28. Hyman BT, Gomez-Isla T, Briggs M, et al. Apolipoprotein E and cognitive change in the elderly population. Ann Neurol 1996;40:55-66.
29. Farrer LA, Brin MF, Elsas L, et al. Statement on use of apolipoprotein E testing for Alzheimer's disease. JAMA 1995; 274:1627-1629.
30. National Institute on Aging/Alzheimer's Association Working Group. Apolipoprotein E genotyping in Alzheimer's disease. Lancet 1996;347:1091-1095.
31. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
32. Roses AD. Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease. Ann Neurol 1995;38:6-14.
33. Saunders AM, Hulette C, Welsh-Bohmer KA, et al. Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet 1996;348:90-93.
34. Kamboh MI, Sephernia B, Ferrell RE. Genetic studies of human apolipoproteins. VI. Common polymorphism of apolipoprotein E in blacks. Dis Markers 1989;7:49-55.
35. Huang DY, Goedert M, Jakes R, et al. Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease. Neurosci Lett 1994;182:55-58.
36. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta-peptide: isoform-specific effects and implications for late-onset Alzheimer's disease. Proc Natl Acad Sci USA 1993;90:8098-8102.
37. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nature Genet 1996;14:55-61.
38. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer's disease. JAMA 1995;273:942-947.
39. Davies P, Maloney AL. Selective loss of central cholinergic neurons in Alzheimer's disease [letter]. Lancet 1976;2:1403.
40. Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10:122-126.
41. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992;268:2523-2529.
42. Knapp MJ, Knopman DS, Solomon PR, et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
43. Report of the Peripheral and Central Nervous System Drugs Advisory Committee Meeting, 1989, Jul 7. Rockville, MD: Department of Health and Human Services, Public Health Service, Food and Drug Administration, 1989;227.
44. Schneider LS, Farlow MR. Predicting response to cholinesterase inhibitors in Alzheimer's disease: possible approaches. CNS Drugs 1995;4:144-124.
45. Poirier J, Delisle M-C, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci USA 1995;92: 12260-12264.
46. Farlow MR, Lahiri D, Hui S, Davignon J. Apolipoprotein E genotype predicts response to tacrine in Alzheimer's disease [abstract]. Neurology 1996;46(suppl 2):A217.